We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

CT Reveals COVID-19 Alters Gray-Matter Volume

By MedImaging International staff writers
Posted on 31 May 2021
Print article
Image: Subplots of GMV in superior/medial/middle frontal gyri (Photo courtesy of Georgia Institute of Technology)
Image: Subplots of GMV in superior/medial/middle frontal gyri (Photo courtesy of Georgia Institute of Technology)
A new computed tomography (CT) study reveals that some COVID-19 patients have reduced gray-matter volume (GMV) in the frontal-temporal lobe of the brain.

Researchers at the Georgia Institute of Technology (Georgia Tech; Atlanta, GA, USA), Georgia State University (Atlanta, USA), the University of Brescia (Italy), and other institutions conducted a retrospective study that used source-based morphometry (SBM) analysis of CT scans in 120 neurological patients (58 patients with COVID-19 and 62 patients without, matched for age, gender, and diseases) to identify GMV changes underlying COVID-19 infection. Patients' disability levels were assessed with the six-point modified Rankin scale, at preadmission, discharge, and six-month follow-up.

The results showed lower GMV in superior/medial/middle frontal gyri that was significantly associated with a higher level of disability at both discharge and at six months follow-up, even when controlling for cerebrovascular diseases (CVD). GMV in the frontal gyri was significantly reduced in patients receiving oxygen therapy and in patients with agitation, compared to patients not receiving oxygen therapy. Patients with fever also presented significant GMV reduction in inferior/middle temporal gyri and the fusiform gyrus compared to patients without fever.

Conversely, patients with COVID-19 showed no significant GMV differences when compared to patients without COVID-19 in any brain region. According to the researchers, this suggests that COVID-19 may affect the frontal-temporal network in a secondary manner through fever or lack of oxygen, and that the gray-matter changes in the frontal region may also underlie the mood disturbances commonly exhibited by COVID-19 patients. The study was published on May 11, 2021, in Neurobiology of Stress.

“People with higher levels of disability at discharge from the hospital and six months later had reduced gray-matter volume in the superior, medial, and middle frontal gyri,” said lead author Kuaikuai Duan, PhD, of Georgia Tech, and colleagues. “Science has shown that the brain's structure affects its function, and abnormal brain imaging has emerged as a major feature of COVID-19. The frontal-temporal network could potentially be employed as a biomarker for prognosis and evaluation of treatment of COVID-19.”

Grey matter is an important component of the central nervous system (CNS), consisting of neuron cells, dendrites, unmyelinated axons, glial cells (such as astrocytes and oligodendrocytes), synapses, and capillaries. It is distinguished from white matter in that it contains numerous cell bodies and relatively few myelinated axons, while white matter contains relatively few cell bodies and is composed chiefly of long-range myelinated axons. The color difference arises mainly from the whiteness of myelin.

Related Links:
Georgia Institute of Technology
Georgia State University
University of Brescia



Print article
Radcal
CIRS

Channels

Industry News

view channel
Illustration

Fujifilm Introduces AI-Powered Chest X-Ray Software in Collaboration with Lunit

Fujifilm Corporation (Tokyo, Japan) has announced that its software for analyzing chest X-ray developed with the core artificial intelligence (AI) technology of Lunit (Seoul, Korea) will be commercially... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.